For the 2024 reporting year, the following ASCO measures are available in the Merit-based Incentive Payment System (MIPS) reporting program. Select ASCO measures are also included in the MIPS Oncology/Hematology Specialty Measure Set, as well as the Advancing Cancer Care MVP.

MIPS Value Pathways (MVPs) are a reporting option to fulfill MIPS reporting requirements. Each MVP consists of a subset of measures and activities related to a specialty or medical condition.

The Advancing Cancer Care MVP focuses on the treatment and management of cancer care. The measures included in this MVP assess three critical areas: 1) the patient experience of care, 2) end of life care, and 3) appropriate diagnostics along with possible treatment options for different cancer diagnoses.

The MIPS Oncology/Hematology Specialty Measure Set can be viewed by selecting  Oncology/Hematology from the Specialty Measure Set dropdown list at Explore Measures & Activities (cms.gov). The CMS MIPS historical quality benchmarks for ASCO MIPS measures are available at Benchmarks (cms.gov)

MIPS Clinical Quality Measures (CQMs) and electronic Clinical Quality Measures (eCQMs)

These oncology measures are available for reporting to CMS in the MIPS program.

Quality ID

(QPP/CBE)

Measure Title

Availability

QPP 143

(CBE 0384)

Oncology: Medical and Radiation-Pain Intensity Quantified (CQM)
  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

CMS157v10

(CBE 0384e)

Oncology Medical and Radiation-Pain Intensity Quantified (eCQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 144

(CBE 0383)

Oncology: Medical and Radiation-Plan of Care for Pain (CQM)
  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 450

(CBE 1858)

Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer (CQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 451

(CBE 1859)

RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy (CQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 452

(CBE 1860)

Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (CQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 453

(CBE 0210)

Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score - better) (CQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP

QPP 457

(CBE 0216)

Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better) (CQM)

  • MIPS
  • MIPS Oncology/Hematology Specialty Measure Set
  • Advancing Cancer Care MVP